Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Popat on the Rationale for Assessing JNJ-5322 in Relapsed/Refractory Myeloma

September 8th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

SC Daratumumab Prolongs PFS in High-Risk Smoldering Myeloma

September 5th 2025

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

Addressing Challenges to Bispecific Integration Across Practice Settings in MM

September 4th 2025

Panelists discuss how academic centers can partner with community practices through early engagement, initial step-up dosing support, and education to overcome barriers to bispecific adoption.

EHA 2025 Data Updates: RedirecTT-1 -Talquetamab + Teclistamab

September 4th 2025

Panelists discuss how the RedirecTT-1 combination of talquetamab and teclistamab shows promising efficacy in extramedullary disease (EMD) with a 79% overall response rate, though with increased infectious complications.

Dr Raza on Unmet Needs in R/R Myeloma With Extramedullary Disease

September 2nd 2025

Shahzad Raza, MD, highlights the challenges associated with managing relapsed/refractory multiple myeloma with extramedullary disease.

FDA Approves New Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

September 2nd 2025

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Dr Landgren on the Rationale for Assessing Daratumumab Plus KRd in Newly Diagnosed Myeloma

August 29th 2025

C. Ola Landgren, MD, PhD, discusses the use of MRD as an early end point in a study evaluating daratumumab plus KRd in newly diagnosed multiple myeloma.

Clinical Strategies for Managing GPRC5D-Related Adverse Events

August 28th 2025

Panelists discuss how to identify and manage GPRC5D-related toxicities, including skin rash, nail problems, and dysgeusia, emphasizing patient education, nutritional support, and dose modification strategies.

Bispecific Step-Up Dosing Models in R/R MM: Institutional Approaches and Protocols

August 28th 2025

Panelists discuss how they've transitioned to outpatient step-up dosing models with robust supportive care protocols, including pneumocystis jirovecii pneumonia (PJP) prophylaxis, intravenous immunoglobulin (IVIG) therapy, and hospital-at-home support teams.

Dr Dimopoulos on BVd vs DVd in Relapsed/Refractory Multiple Myeloma With High-Risk Cytogenetic Features

August 27th 2025

Meletios A. Dimopoulos, MD, discusses the efficacy of BVd vs DVd in patients with relapsed or refractory multiple myeloma.

Daratumumab Plus KRd Offers a New Standard of Care in Newly Diagnosed Multiple Myeloma

August 27th 2025

C. Ola Landgren, MD, PhD, discusses the feasibility of daratumumab plus KRd as a standard of care for the management of newly diagnosed multiple myeloma.

A New Era In Multiple Myeloma Treatment: Advances and Future Directions

August 26th 2025

The emergence of immunotherapies and targeted agents has ushered in a new era in relapsed/refractory multiple myeloma.

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma

August 25th 2025

Meletios A. Dimopoulos, MD, discusses the efficacy and safety of elranatamab plus daratumumab and lenalidomide in transplant-ineligible multiple myeloma.

Talquetamab/Teclistamab May Address Need for Improved Survival Outcomes in R/R Myeloma With Extramedullary Disease

August 25th 2025

Shahzad Raza, MD, discusses updated outcomes with talquetamab and teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Dr Sidana on the Efficacy of Second-Line Cilta-Cel in Relapsed/Refractory Myeloma

August 21st 2025

Surbhi Sidana, MD, discusses the PFS and OS benefit of second-line cilta-cel in patients with relapsed/refractory multiple myeloma.

Clinical Perspectives: Analyzing Real-World Data With Bispecifics in R/R MM

August 21st 2025

Panelists discuss how real-world bispecific data shows slight efficacy drops compared with clinical trials but still demonstrates effectiveness in patients who wouldn't meet trial criteria, particularly for bridging to chimeric antigen receptor (CAR) T-cell therapy

Strategic Use of BCMA- and GPRC5D-Directed Bispecifics in R/R MM

August 21st 2025

Panelists discuss how bispecific antibodies are integrated into relapsed/refractory myeloma treatment, with GPRC5D-targeted agents preferred for bridging to chimeric antigen receptor (CAR) T-cell therapy and B-cell maturation antigen (BCMA)-targeted agents for non-CAR T candidates.

Oncology Conferences to Watch in the Second Half of 2025

August 20th 2025

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.